Aviva Fohrer
Addiction Medicine · Narberth, PANPI 1710109608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 32.4% of the total.
Across 146 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$948
- Axsome Therapeutics, Inc.$407
- Indivior Inc.$355
- Braeburn Inc.$308
- Otsuka America Pharmaceutical, Inc.$300
- Bausch Health US, LLC$196
- plus $411 from 6 others
Across 158 payments — averaging $931.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orexo US, Inc.$76K
- Indivior Inc.$72K
What the payments were for
- Consulting fees$1254%
- Food & beverage$2,80096%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $948 |
| Axsome Therapeutics, Inc. | 13 | $407 |
| Indivior Inc. | 22 | $355 |
| Braeburn Inc. | 13 | $308 |
| Otsuka America Pharmaceutical, Inc. | 11 | $300 |
| Bausch Health US, LLC | 9 | $196 |
| Orexo US, Inc. | 15 | $166 |
| Alkermes, Inc. | 6 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,925 in reported general payments places this provider in the 85th percentile of 82 addiction medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naltrexone Hcl | 14 | $468 |
| Bupropion XlBupropion Hcl | 11 | $297 |
| Bupropion Hcl SrBupropion Hcl | 12 | $95 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Narberth
- Karen SeesKane$928K
- Christopher DavisYork$226K
- William SantoroWest Reading$93K
- Philip MooreLemoyne$6K
- Carol LudolphHuntingdon Valley$5K
- Henry LuuWest Chester$5K
- Bernard HarrisNewtown Square$4K
- Jacques ChellyPittsburgh$4K
- Michael Halldu Bois$4K
- Adam ScioliWernersville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.